Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
  • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
  • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• This invention relates to penicillin derivatives and more particularly to the o-tolyl ester of an ⁇ -carboxy 6-methoxy-penicillin.
• the present invention is based on the discovery that the ⁇ -ortho-tolyl ester of ⁇ -carboxy-3-thienylmethyl 6-methoxy-penicillin exhibits higher bioavailability after oral administration in mammals, such as man than other esters such as, for example, the phenyl ester.
• Suitable salts of the 3-carboxylic acid group of the compound of formula (II) include metal salts, eg aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium, and ammonium or substituted ammonium salts, for example those with lower alkylamino such as triethylamine, hydroxy-lower alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylamine, N,N-dibenzylethylenediamine, 1-ephenamine, N-ethylpiperidine, N-benzyl- ⁇ -phenethylamine, dehydroabeitylamine, N,N'-bisdehydroabietylethylenediamine, or bases of the pyridine type such as pyridine, collidine
• the carbon atom marked * in formula (II) is asymmetric.
• This invention includes both optically active isomers at that position as well as the D,L-mixture.
• Suitable groups which permit acylation to take place and which are optionally present on the amino group of the starting material of the formula (III) include N-silyl, N-stannyl and N-phosphorus groups, for example trialkylsilyl groups such as trimethylsilyl, trialkyltin groups such as tri-n-butyltin, groups of formula --P.R a R b wherein R a is an alkyl, haloalkyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy or dialkylamino group, R b is the same as R a or is halogen or R a and R b together form a ring; suitable such phosphorus groups being --P(OC 2 H 5 ) 2 , --P(C 2 H 5 ) 2 , ##STR6##
• Suitable carboxyl-blocking derivatives for the group --CO 2 R x in formula (III) include salts, ester, and anhydride derivatives of the carboxylic acid.
• the derivative is preferably one which may readily be cleaved at a later stage of the reaction.
• Suitable salts include inorganic salts, for example alkali metal salts such as the sodium salt, tertiary amine salts, such as those with tri-lower-alkylamines, N-ethylpiperidine, 2,6-lutidine, pyridine, N-methylpyrrolidine, dimethylpiperazine.
• a preferred salt is with triethylamine.
• Suitable ester-forming carboxyl-blocking groups are those which may be removed under conventional conditions.
• Such groups for R x include benzyl, p-methoxybenzyl, 2,4,6-trimethylbenzyl, 3,5-di-t-butyl-4-hydroxybenzyl, benzoylmethyl, p-nitrobenzyl, 4-pyridylmethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, t-amyl, diphenylmethyl, triphenylmethyl, adamatyl, 2-benzyloxyphenyl, 4-methylthiophenyl, tetrahydrofur-2-yl, tetrahydropyran-2-yl, pentachlorophenyl, p-toluenesulphonylethyl, methoxymethyl, a silyl, stannyl or phosphorus-containing group, such as described above, an oxime radical of formula --N ⁇ C
• the carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular R x group, for example, acid--catalysed hydrolysis, or by enzymatically--catalysed hydrolysis, or by hydrogenation.
• the hydrolysis must of course be carried out under conditions to which the ortho-tolyl ester group in the side-chain is stable.
• a reactive N-acylating derivative of the acid (IV) is employed in the above process.
• Suitable N-acylating derivatives include an acid halide, preferably the acid chloride or bromide.
• Acylation with an acid halide may be affected in the presence of an acid binding agent for example tertiary amine (such as triethylamine or dimethylaniline), an inorganic base (such as calcium carbonate or sodium bicarbonate) or an oxirane, which binds hydrogen halide liberated in the acylation reaction.
• the oxirane is preferably a (C 1-6 )-1,2-alkylene oxide--such as ethylene oxide or propylene oxide.
• the acylation reaction using an acid halide may be carried out at a temperature in the range -50° C. to +50° C., preferably -20° C. to +20° C., in aqueous or non-aqueous media such as aqueous acetone, ethyl acetate, dimethylacetamide, dimethylformamide, acetonitrile, dichloromethane, 1,2-dichloroethane, or mixtures thereof.
• the reaction may be carried out in an unstable emulsion of water-immiscible solvent, especially an aliphatic ester or ketone, such as methyl isobutyl ketone or butyl acetate.
• the acid halide may be prepared by reacting the acid (IV) or a salt thereof with a halogenating (eg chlorinating or brominating) agent such as phosphorus pentachloride, thionyl chloride or oxalyl chloride.
• a halogenating agent such as phosphorus pentachloride, thionyl chloride or oxalyl chloride.
• the N-acylating derivative of the acid (IV) may be symmetrical or mixed anhydride.
• Suitable mixed anhydrides are alkoxyformic anhydrides, or anhydrides with, for example carbonic acid monoesters, trimethyl acetic acid, thioacetic acid, diphenylacetic acid, benzoic acid, phosphorus acids (such as phosphoric or phosphorous acids), sulphuric acid or aliphatic or aromatic sulphonic acids (such as p-toluenesulphonic acid).
• the mixed or symmetrical anhydrides may be generated using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. When a symmetrical anhydride is employed, the reaction may be carried out in the presence of 2,4-lutidine as catalyst.
• Alternative N-acylating derivatives of acid (IV) are the acid azide, or activated esters such as esters with 2-mercaptopyridine, cyanomethanol, p-nitrophenol, 2,4-dinitrophenol, thioalcohols such as thiophenol, methanethiol, ethanethiol and propanethiol, halophenols, including pentachlorophenol, monomethoxyphenol or 8-hydroxyquionline, N-hydroxysuccinimide or 1-hydroxybenztriazole; or amides such as N-acylsaccharins or N-acylphthalimides; or an alkylidine iminoester prepared by reaction of the acid (IV) with an oxime.
• esters such as esters with 2-mercaptopyridine, cyanomethanol, p-nitrophenol, 2,4-dinitrophenol, thioalcohols such as thiophenol, methanethiol, ethanethiol and propanethiol, hal
• reactive N-acylating derivatives of the acid (IV) include the reactive intermediate formed by reaction in situ with a condensing agent such as a carbodiimide, for example N,N'-diethyl-,N,N'-dipropyl- or N,N'-diisopropylcarbodiimide, N,N'-di-cyclohexylcarbodiimide; or N-ethyl-N'- ⁇ -dimethylaminopropylcarbodiimide; a suitable carbonyl compound, for example N,N'-carbonyldiimidazole or N,N'-carbonylditriazole; an isoxasolinium salt, for example N-ethyl-5-phenylisoxazolinium-3-sulphonate or N-t-butyl-5-methylisoxazolinium perchlorate; or an N-alkoxycarbonyl-2-alkoxy-1,2-dihydroquinoline, such
• condensing agents include Lewis acids (for example BBr 3 --C 6 H 6 ); or a phosphoric acid condensing agent such as diethylphosphorylcyanide.
• the condensation reaction is preferably carried out in an organic reaction medium, for example methylene chloride, dimethylformamide, acetonitrile, alcohol, benzene, dioxan or tetrahydrofuran.
• a suitable agent for preparing an imino halide is an acid halide in the presence of an acid binding agent such as a tertiary amine, eg pyridine, triethylamine, or N,N-dimethylaniline.
• an acid binding agent such as a tertiary amine, eg pyridine, triethylamine, or N,N-dimethylaniline.
• suitable acid halides are phosphorus pentachloride, phosgene, phosphorous pentabromide, phosphorus oxychloride, oxalyl chloride and p-toluene sulphonic acid chloride. Phosphorus pentachloride and phosphorus oxychloride are preferred.
• the reaction may be conducted under cooling, preferably at temperatures from 0° C. to -30° C. when phosphorus pentachloride is employed.
• the amount of the tertiary amine is preferably 3-5 mols per
• the resulting imino compounds are then treated to introduce a --QR f group onto the imino carbon atom.
• This is preferably effected by reacting the imino halide with a corresponding alcohol.
• suitable alcohols for reaction with the imino halide are aliphatic alcohols containing from 1 to 12 carbon atoms, preferably 1 to 5 carbon atoms, such as methanol, ethanol, propanol, isopropyl alcohol, amyl alcohol and butyl alcohol, and aralkyl alcohols such as benzyl alcohol and 2-phenylethanol.
• the reaction of the alcohol with the imino halide is preferably effected in the presence of an acid binding agent, such as a tertiary amine, preferably pyridine, and the reaction is usually carried out without isolating the imino halide from the reaction mixture.
• an acid binding agent such as a tertiary amine, preferably pyridine
• N-acylating derivative of an acid of formula (IV) is caused to react with an N-acylating derivative of an acid of formula (IV).
• N-acylating derivatives and the conditions for carrying out acylations also apply in this case.
• the presence of a tertiary amine such as pyridine or N,N-dimethylaniline in the reaction system is preferred.
• the product is treated with water.
• the water treatment may be conducted together with the isolation of the desired material. That is the reaction mixture may be added to water or a saturated aqueous solution of sodium chloride and then the aqueous layer formed is separated from the organic solvent layer.
• the compounds of formula (II) may also be prepared by esterification of a compound of formula (VII) or a salt thereof: ##STR10## wherein R x is a carboxyl blocking group; with compound of formula (VIII): ##STR11## and thereafter if necessary carrying out one or more of the following steps:
• Esterification may be performed by any conventional method, for example by reaction of the free acid with a compound of formula (VIII) in the presence of a catalyst.
• a reactive esterifying derivative of the compound of formula (VII) may be reacted with the compound of formula (VIII) or an alkali metal or alkaline earth metal salt thereof.
• Suitable salts include the lithium, sodium or magnesium salts.
• Reactive esterifying derivatives of the acid (VII) include the reactive intermediate formed by reaction in situ with a condensing agent such as a carbodiimide, for example N,N-diethyl-, dipropyl- or diisopropylcarbodiimide, N,N'-di-cyclohexylcarbodiimide, or N-ethyl-N'- ⁇ -dimethylaminopropylcarbodiimide; a suitable carbonyl compound, for example N,N'-carbonyldiimidazole or N,N'-carbonylditriazole; an isoxasolinium salt, for example N-ethyl-5-phenylisoxazolinium-3-sulphonate or N-t-butyl-5-methylisoxazolinium perchlorate; or an N-alkoxycarbonyl-2-alkoxy-1,2-dihydroquinoline, such as N-ethoxycarbonyl-2-eth
• condensing agents include Lewis acids (for example BBr 3 --C 6 H 6 ); or a phosphoric acid condensing agent such as diethylphosphorylcyanide.
• the condensation reaction is preferably carried out in an organic reaction medium, for example methylene chloride, dimethylformamide, acetonitrile, alcohol, benzene, dioxan or tetrahydrofuran.
• a further method for the preparation of compounds of formula (II) comprises reacting a compound of formula (IX): ##STR12## wherein R x is a carboxyl blocking group and R 4 is C 1-6 alkyl, benzyl or an aryl group; A) with chlorine or bromine at -25° to -80° C. and subsequently decomposing the resultant halosulphonium halide with methanol and a base; or B) with methanol in the presence of a metal ion, such as a tellurium (III), lead (IV), silver, copper (II), bismuth (V), mercury, lead, cadmium or thallium salt, and thereafter if necessary:
• a metal ion such as a tellurium (III), lead (IV), silver, copper (II), bismuth (V), mercury, lead, cadmium or thallium salt, and thereafter if necessary:
• this latter reaction is carried out at -50° to +25° C. in a solvent.
• a further method for the preparation of compounds of formula (II) comprise hydrolysis of a compound of formula (X): ##STR13## wherein R x represents a carboxyl blocking group and thereafter if necessary carrying out one or more of the following steps:
• the hydrolysis is carried out at a pH in the range 1 to 5 preferably 2 to 4, at ambient temperature.
• Suitable solvents include tetrahydrofuran or acetone.
• the intermediate of formula (X) may be prepared by
• Suitable acid halides are phosphorus pentachloride, phosgene, phosphorous pentabromide, phosphorus oxychloride, oxalyl chloride and p-toluene sulphonic acid chloride.
• Phosphorus pentachloride and phosphorus oxychloride are preferred.
• the reaction may be conducted under cooling, preferably at temperatures from +5° C. to -30° C. (preferably about 0° C.) when phosphorus pentachloride is employed.
• the amount of the tertiary amine is preferably 3-5 mols per mol of phosphorus pentachloride. It is also preferable to use the phosphorus halide in an amount in excess of that of the starting material.
• Suitable double bond addition reagents for step (b) of the above process include diatomic halogen molecules or a compound of formula Br.N 3 .
• the double bond addition reagent is chlorine.
• the reaction is suitably carried out in an inert solvent, such as tetrahydrofuran or a halogenated hydrocarbon e.g. chloroform, at low temperatures such as +20° C. to -100° C. preferably -50° C. to -80° C., e.g. at about -70° C.
• an inert solvent such as tetrahydrofuran or a halogenated hydrocarbon e.g. chloroform
• the resulting product is then reacted with an alkali metal or thallium methoxide of formula CH 3 OM.
• M may be sodium or potassium, but is preferably lithium.
• the reaction is generally carried out in a polar aprotic solvent, preferably methanol, preferably in the presence of another inert solvent, such as tetrahydrofuran as long as it does not freeze at the temperature of the reaction.
• the reaction is suitably carried out at low temperature, preferably in the range -40° C. to -80° C., preferably about -75° C.
• the reagent CH 3 OM may be formed in situ by the use of methanol together with a base such as butyl lithium, lithium diisopropylamide, lithium or sodium hydride or preferably butyl lithium.
• the antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or verterinary medicine, by analogy with other antibiotics, and the invention therefore includes within its scope a pharmaceutical composition comprising a compound of formula (II) above together with a pharmaceutical carrier or excipient.
• compositions may be formulated for administration by any route, although an oral administration is preferred.
• the compositions may be in the form of tablets, capsules, powders, granules, lozenges, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
• Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
• the tablets may be coated according to methods well known in normal pharmaceutical practice.
• Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired convention flavouring or colouring agents.
• suspending agents for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monoo
• Suppositories will contain conventional suppository bases, eg cocao-butter or other glyceride.
• fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
• the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
• the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
• adjuvants such as local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
• the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection is supplied to reconstitute the liquid prior to use.
• Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
• the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
• a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
• compositions may contain from 0.1% to 99% by weight, preferably from 10% to 60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50 to 500 mg, of the active ingredient.
• the dosage as employed for adult human treatment will preferably range from 100 to 3000 mg, per day, for instance 1500 mg, per day, depending on the route and frequency of administration.
• compositions of the invention may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics may be employed.
• compositions also comprise a compound of formula (XIII) or a pharmaceutically acceptable salt or ester thereof: ##STR16## wherein A is hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, mono- or di-hydrocarbylsubstituted amino, or mono- or di-acylamino.
• A is hydroxyl, i.e. the compound of formula (X) is clavulanic acid or a pharmaceutically acceptable salt thereof, in particular an alkali metal salt.
• the filtrate was extracted successively with 0.4 N sodium bicarbonate (25 ml), 0.2 N sodium bicarbonate (50 ml, 25 ml) then water (25 ml).
• the combined aqueous extracts were washed with ether then acidified to pH4.0 with 40% phosphoric acid and extracted with ether (3 ⁇ 50 ml).
• the ether solution was washed with water (2 ⁇ 50 ml) and saturated brine (25 ml) dried over magnesium sulphate and evaporated to a foam in vacuo, 3.81 g.
• a sample crystallised from diethyl ether had C,54.58,54.18; H, 4.76, 4.78; N, 5.40, 5.45; S, 12.36, 12.49%.
• C 23 H 24 N 2 O 7 S 2 requires C,54.75, H, 4.79; N, 5.55; S, 12.70%.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Oncology (AREA)
• Pharmacology & Pharmacy (AREA)
• Communicable Diseases (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cephalosporin Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10527789

Family Applications (1)

Country Status (18)

Families Citing this family (1)

Citations (3)

Family Cites Families (4)

• 1983
  • 1983-01-12 IL IL67672A patent/IL67672A0/xx unknown
  • 1983-01-18 EP EP83300235A patent/EP0084948B1/en not_active Expired
  • 1983-01-18 DE DE8383300235T patent/DE3374316D1/de not_active Expired
  • 1983-01-18 AT AT83300235T patent/ATE30592T1/de active
  • 1983-01-20 PL PL24023883A patent/PL240238A1/xx unknown
  • 1983-01-20 PL PL24581283A patent/PL245812A1/xx unknown
  • 1983-01-20 NO NO830183A patent/NO830183L/no unknown
  • 1983-01-20 PL PL24581483A patent/PL245814A1/xx unknown
  • 1983-01-20 CA CA000419917A patent/CA1217479A/en not_active Expired
  • 1983-01-20 AU AU10640/83A patent/AU560185B2/en not_active Ceased
  • 1983-01-20 ZA ZA83377A patent/ZA83377B/xx unknown
  • 1983-01-20 FI FI830192A patent/FI830192L/fi not_active Application Discontinuation
  • 1983-01-20 NZ NZ203065A patent/NZ203065A/en unknown
  • 1983-01-20 PL PL24581383A patent/PL245813A1/xx unknown
  • 1983-01-20 GR GR70300A patent/GR77867B/el unknown
  • 1983-01-20 US US06/459,668 patent/US4455314A/en not_active Expired - Fee Related
  • 1983-01-20 DK DK22983A patent/DK22983A/da not_active Application Discontinuation
  • 1983-01-20 PT PT76128A patent/PT76128B/pt unknown
  • 1983-01-21 JP JP58008610A patent/JPS58128389A/ja active Pending
  • 1983-01-21 KR KR1019830000224A patent/KR840003258A/ko not_active Application Discontinuation
  • 1983-01-21 ES ES519190A patent/ES8403135A1/es not_active Expired
  • 1983-09-14 ES ES525614A patent/ES525614A0/es active Granted
  • 1983-09-14 ES ES525612A patent/ES8503004A1/es not_active Expired
  • 1983-09-14 ES ES525613A patent/ES8503005A1/es not_active Expired

Patent Citations (3)

Also Published As

Similar Documents

Legal Events